source
- GSK and Ionis receive FDA nod for Hibsago, a potential functional cure for chronic hepatitis BThe U.S. Food and Drug Administration has cleared Hibsago, a collaborative product of GSK and Ionis, as the first therapy of its kind aimed at chronic hepatitis B. The medicine is to be added to s…
- Nouscom secures €120M to advance off-the-shelf cancer vaccine for Lynch syndromeSwiss biotech Nouscom announced a €120 million (about $135 million) Series D financing round. The capital will fund a registration-enabling pivotal trial of its cancer-preventing vaccine candidate.…